# Aerin Medical
Aerin Medical Inc. is a privately held medical-device company founded in 2011 and headquartered in [Mountain View, California](https://www.edgepedia.org/mountain-view-california), that makes FDA-cleared, temperature- and impedance-controlled radiofrequency systems, sold under the names VivAer and RhinAer, for in-office treatment of nasal airway obstruction and chronic rhinitis.[1](https://www.sec.gov/Archives/edgar/data/1536647/000153664724000001/0001536647-24-000001.txt) • [2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) The company described itself as privately held and venture-backed in its January 2025 funding announcement, and no acquisition, public listing, or closure appears in the record through that date.[3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth)
| Fact | Detail |
|---|---|
| Founded | 2011 (Delaware incorporation; name-change date recorded as 2011-12-07)[4](https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001536647&action=getcompany&count=40&dateb=&owner=include&type=D) |
| Headquarters | 2565 Leghorn Street, Mountain View, CA 94043[1](https://www.sec.gov/Archives/edgar/data/1536647/000153664724000001/0001536647-24-000001.txt) |
| Products | VivAer (nasal airway obstruction) and RhinAer (chronic rhinitis), temperature- and impedance-controlled radiofrequency[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) |
| Total raised | $145,152,948 across nine Form D equity rounds, 2011 to December 2024[5](https://www.dealdata.net/company-profile/0001536647/) |
| Notable investors | KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group; Ares Management Credit (debt facility)[3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) |
| Patients treated | More than 200,000 as of March 25, 2026 (company claim)[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) |
| Status | Privately held, venture-backed, per the company's January 2025 announcement[3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) |
## History and founding
Aerin Medical was incorporated in Delaware in 2011. EDGAR records the former name "Aerin Medical, Inc." with a name-change date of 2011-12-07, and the first Form D notice was filed on 2011-12-12.[4](https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001536647&action=getcompany&count=40&dateb=&owner=include&type=D) The company's earliest filings in the record list a business address of 232 E Caribbean Dr, Sunnyvale, California, before the later move to Mountain View.[4](https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001536647&action=getcompany&count=40&dateb=&owner=include&type=D)
The December 2024 Form D lists [Scott Wolf](https://www.edgepedia.org/scott-wolf), Matthew Brokaw, Irina Ridley, Derrick Sung, Matthew Salkeld, and Andre Cheng as executive officers, and Nael Kassar, Karen Long, William Facteau, David Thrower, and Gregory Garfield as directors; Matt Brokaw is chief executive officer according to the company's January 2025 funding announcement.[1](https://www.sec.gov/Archives/edgar/data/1536647/000153664724000001/0001536647-24-000001.txt) • [3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) No source in the record independently verifies who founded the company or the founders' earlier medical-device careers.
## Products and technology
Aerin's systems deliver temperature- and impedance-controlled radiofrequency energy. VivAer treats nasal airway obstruction; RhinAer treats chronic rhinitis by targeting the posterior nasal nerve.[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) • [6](https://www.massdevice.com/aerin-medical-launches-next-gen-rhinaer/) According to the company, procedures are performed in-office under local anesthesia, with no incisions and minimal downtime.[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/)
Regulatory clearances, as stated by the company: the VivAer Stylus received CE Mark in 2016 and FDA 510(k) clearance in December 2017; RhinAer received FDA 510(k) clearance in December 2019 and CE Mark in 2020.[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) In October 2025, MassDevice independently reported the launch of a next-generation RhinAer device for chronic rhinitis.[6](https://www.massdevice.com/aerin-medical-launches-next-gen-rhinaer/)
## Clinical evidence
The company summarizes its evidence base as nearly 1,000 patients enrolled in clinical studies globally, contributing to more than 40 peer-reviewed publications.[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) The most detailed study in the record is a three-year, prospective, single-arm, open-label, multicenter study of RhinAer posterior nasal nerve ablation, published in the American Journal of Rhinology & Allergy and summarized in a company release: it enrolled 129 patients across 19 sites in the United States and Germany.[7](https://aerinmedical.com/company/news-and-media/three-year-study-confirms-lasting-chronic-rhinitis-symptom-relief-and-quality-of-life-improvements-with-rhinaer/)
At three years, the study reported a 58% improvement in total nasal symptom scores (rTNSS) and a 60% improvement in MiniRQLQ quality-of-life scores (p < 0.001). Only 2 of 129 patients (1.6%) underwent reintervention related to posterior nasal nerve ablation, and no serious device- or procedure-related adverse events were reported during follow-up.[7](https://aerinmedical.com/company/news-and-media/three-year-study-confirms-lasting-chronic-rhinitis-symptom-relief-and-quality-of-life-improvements-with-rhinaer/) These figures come from a company summary of a single-arm study without a sham or comparator group, so they describe symptom change after treatment rather than effect size versus standard care.
## Funding and investors (by the numbers)
Aerin Medical raised a total of $145,152,948 across nine Form D equity rounds between 2011 and December 2024, per a compilation of its SEC Form D filings.[5](https://www.dealdata.net/company-profile/0001536647/) Eight of the nine rounds, by first-sale date and amount sold:
| Date | Amount sold | Offering size |
|---|---|---|
| 2011-11-30 | $125,000 | $1,060,000 |
| 2012-10-09 | $125,000 | $1,000,000 |
| 2014-02-06 | $524,998 | $2,500,000 |
| 2015-07-23 | $6,698,125 | $14,355,003 |
| 2016-03-08 | $10,572,276 | $10,572,276 |
| 2020-08-04 | $49,749,882 | $49,749,882 |
| 2022-04-28 | $34,880,478 | $60,000,000 |
| 2024-12-13 | $32,477,189 | $32,815,188 |
[5](https://www.dealdata.net/company-profile/0001536647/)
The December 2024 Form D, filed 2024-12-30, reported $32,477,189 sold of a $32,815,188 offering with 23 investors and a first sale date of 2024-12-13.[1](https://www.sec.gov/Archives/edgar/data/1536647/000153664724000001/0001536647-24-000001.txt) In January 2025 the company announced the completion of a $32.5 million equity financing led by its major investors KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided a debt facility to refinance existing debt and access additional capital.[3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) The Form D figure and the announced $32.5 million describe the same December 2024 round at slightly different precision.
## Business, reimbursement and traction
According to the company, the procedures are performed in ENT practices in-office under local anesthesia, a model it presents as convenient for patients with minimal downtime.[2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/) The company reported more than 150,000 patients treated as of January 2025 and more than 200,000 as of March 25, 2026, implying roughly 50,000 additional patients in about fourteen months; both figures are company claims.[3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) • [2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/)
MassDevice independently reported in October 2025 that UnitedHealthcare's Medicare Advantage policy now covers RhinAer for treatment of the posterior nasal nerve, effective immediately.[6](https://www.massdevice.com/aerin-medical-launches-next-gen-rhinaer/) No source in the record reports the price of an Aerin console or single-use stylus to practices, or practice-level economics.
## Status and recent developments
Aerin Medical described itself as privately held and venture-backed in January 2025; no acquisition, IPO, or closure appears in the record through that date.[3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) The record shows an April 2022 Form D round of $34.9 million, followed by the December 2024 Form D ($32.5 million announced January 2025) with an Ares Management Credit debt refinancing, the October 2025 next-generation RhinAer launch, the UnitedHealthcare Medicare Advantage coverage decision, and the March 2026 200,000-patient milestone.[1](https://www.sec.gov/Archives/edgar/data/1536647/000153664724000001/0001536647-24-000001.txt) • [3](https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth) • [6](https://www.massdevice.com/aerin-medical-launches-next-gen-rhinaer/) • [2](https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/)
## References
1. Aerin Medical Inc. Form D, filed 2024-12-30 (Accession 0001536647-24-000001), SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1536647/000153664724000001/0001536647-24-000001.txt
2. "Aerin Medical Surpasses 200,000 Patients Treated," Aerin Medical newsroom, March 25, 2026. https://aerinmedical.com/company/news-and-media/aerin-medical-surpasses-200000-patients-treated-with-the-companys-minimally-invasive-solutions-for-chronic-nasal-conditions/
3. "Aerin Announces New Funding to Further Fuel Growth," Business Wire, January 13, 2025. https://www.businesswire.com/news/home/20250113387377/en/Aerin-Announces-New-Funding-to-Further-Fuel-Growth
4. SEC EDGAR filing index for Aerin Medical Inc. (CIK 0001536647), Form D history. https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001536647&action=getcompany&count=40&dateb=&owner=include&type=D
5. AERIN MEDICAL INC. Form D funding history, Dealdata (CIK 0001536647). https://www.dealdata.net/company-profile/0001536647/
6. "Aerin Medical launches next-gen device to treat chronic rhinitis," MassDevice, October 2025. https://www.massdevice.com/aerin-medical-launches-next-gen-rhinaer/
7. "Three-Year Study Confirms Lasting Chronic Rhinitis Symptom Relief and Quality-of-Life Improvements with RhinAer," Aerin Medical newsroom, September 2025. https://aerinmedical.com/company/news-and-media/three-year-study-confirms-lasting-chronic-rhinitis-symptom-relief-and-quality-of-life-improvements-with-rhinaer/
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Medical device makers*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026; Oct 25, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license